Otsuka 1xbet 한국armaceutical Co., Ltd.

• VONOSAP^®1xbet 한국 and VONOSAP^®1xbet 한국, each a triple-drug blister pack containing the potassium-competitive acid blocker TAKECAB® tablet developed by Takeda for primary eradication ofHelicobacter pylori (H. pylori), are now available in Japan.
• VONOPION^®1xbet 한국, a triple-drug blister 1xbet 한국 containing TAKECAB® tablet for secondary eradication ofH. pylori, is also now available in Japan.
• Takeda and 1xbet 한국 will implement promotional activities on VONOSAP^®1xbet 한국, VONOSAP^®1xbet 한국^®1xbet 한국 for eradication ofH. pylori, in accordance with the agreement reached in March 2014 for co-promotion of TAKECAB® tablet, thereby addressing healthcare needs in acid-related disorders .

Takeda 1xbet 한국armaceutical Company Limited (head office, Chuo-ku, Osaka; President and CEO, Christo1xbet 한국e Weber; hereafter "Takeda") and Otsuka 1xbet 한국armaceutical Co., Ltd. (Head office, Chiyoda-ku, Tokyo; President and Representative Director, Tatsuo Higuchi; hereafter "Otsuka") announced today that VONOSAP^®1xbet 한국 and VONOSAP^®1xbet 한국 (hereafter "VONOSAP") together with VONOPION^®1xbet 한국 (hereafter "VONOPION") forH. pylorieradication are now available in Japan.
VONOSAP is a triple-drug blister 1xbet 한국 combining the acid suppressant ((also called a potassium-competitive acid blocker (P-CAB) based on its mechanisms of action)) TAKECAB® tablet (generic name, vonoprazan fumarate; hereafter "TAKECAB") developed by Takeda, "Amolin^®capsule" (generic name, amoxicillin; hereafter "Amolin") and "Clarith^®tablet" (generic name, clarithromycin) for primary eradication ofH. pylori. VONOPION is a triple-drug blister 1xbet 한국 containing TAKECAB, Amolin and Fragile^®tablet (generic name, metronidazole) for secondary eradication ofH. pylori.

"Since 2002, Takeda has made available for patients of acid-related disease a triple-drug blister 1xbet 한국 containing two antibiotics used forH. pylorieradication and the acid suppressant "TAKEPRON" with the aim of improving patient adherence," said Masato Iwasaki, 1xbet 한국.D., director, president of Japan 1xbet 한국arma Business Unit of Takeda. "I am delighted that together with Otsuka, an excellent co-promotion partner, we are able to offer patients a new triple-drug blister pack containing TAKECAB, which is known to exert potent and sustained acid-inhibitory effects. Through VONOSAP and VONOPION, we will make further contributions toH. pylorieradication in Japan."

Susumu Tamai, vice president and executive director of 1xbet 한국 commented, "1xbet 한국 has developed a diagnostic system forH. pyloriinfections, enabling a broad contribution from diagnosis to treatment. Through our promotional collaboration with Takeda ofH. pylori1xbet 한국 formulations containing TAKECAB, we are enthusiastic about this opportunity to deliver a new eradication therapy to more patients."

• Helicobacter pyloriare one type of bacteria present in the human stomach and are primarily known to be implicated in the onset of peptic ulcers.H. pylorieradication therapy has been shown to be effective in preventing peptic ulcer recurrence with markedly low peptic ulcer recurrence rates reported following treatment, providing substantial benefits to patients withH. pyloriinfection.

Overview of VONOSAP

Overview of VONOPION